Cavu Biotherapies, Inc.
An early stage translational onco-biotech company with extensive leadership experience in the medical, immuno-oncology, and veterinary arenas focused on providing immune-based solutions to treat cancer and autoimmune diseases. We manufacture and develop adoptive cellular therapy treatments against solid and hematological tumors for pet dogs and humans. Our proprietary technologies include cellular therapy, accelerated generation of novel TCR/CAR, and machine learning algorithms to predict immune health (iScore). Initial entry into the veterinarian market, with few regulatory barriers and lower entry cost, serves as a launch pad for translational applications into humans markets.